RxDoctor Payments Data

Devendra Sharma, MD

General Practice · Garnerville, NYNPI 1811061211

Payments from drug & device makers

$3,075in general payments, 2019–2025

Across 47 payments — averaging $65.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$847
  • Johnson & Johnson$450
  • Teva Pharmaceuticals USA, Inc.$409
  • Otsuka America Pharmaceutical, Inc.$362
  • ANI Pharmaceuticals, Inc.$167
  • Stryker$137
  • plus $703 from 7 others

What the payments were for

  • Food & beverage$3,075100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,075 in reported general payments places this provider in the 90th percentile of 5,764 general practice providers in New York.

See all general practice providers in New York

Medicare billing

Part B allowed, 2024
$159,694
Medicare patients
82
Services billed
1,837

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate14$49,291
EliquisApixaban63$39,278
XareltoRivaroxaban37$14,346
JardianceEmpagliflozin19$11,937
TrulicityDulaglutide11$11,123
NamzaricMemantine Hcl/Donepezil Hcl12$7,423
JanumetSitagliptin Phos/Metformin Hcl16$6,136
JanuviaSitagliptin Phosphate16$5,807
Incruse ElliptaUmeclidinium Bromide12$4,415
Memantine Hcl50$2,299
Atorvastatin Calcium147$2,132
Quetiapine Fumarate70$2,018
Memantine Hcl ErMemantine Hcl38$1,910
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate11$1,864
Aripiprazole11$1,756

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Xarelto$450$63,63751 claims
GSKIncruse Ellipta$125$4,41512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,764 general practice providers in New York.

Other general practice in Garnerville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →